Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2026 09:30 ET | Source: Stemline Therapeutics, Inc.

Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant (ORSERDU®) in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented.The efficacy data highlight how the combination of...
May 28, 2026 09:00 ET | Source: American Oncology Network

American Oncology Network Announces Research Studies to be Presented at ASCO 2026 Annual Meeting

American Oncology Network Announces Research Studies to be Presented at ASCO 2026 Annual Meeting
May 28, 2026 08:00 ET | Source: Medidata Solutions, Inc.

Medidata’s Next-Gen AI Imaging Solution Delivers Unprecedented Speed and Precision for Clinical Trials

NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions, today unveiled its enhanced, AI-powered imaging solution, within the...
May 28, 2026 04:00 ET | Source: Anaveon

Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Anaveon reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 & actively seeks Partners for its Legacy Oncology Portfolio.
May 27, 2026 09:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
May 27, 2026 08:00 ET | Source: Callio Therapeutics

Callio Therapeutics to Present Phase 1 Trial Design of CLIO-8221, Novel Dual-Payload ADC, at ASCO 2026

Callio Therapeutics will present a trial-in-progress poster highlighting the CLIO-8221 Phase 1 trial design at the 2026 ASCO Annual Meeting in Chicago.
May 22, 2026 09:42 ET | Source: 24/7 Market News

This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners

Biotechs continue attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy pla
May 22, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors

Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth
May 22, 2026 08:00 ET | Source: InnoCare Pharma

2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released

The data show that mesutoclax demonstrates outstanding efficacy and safety in treating various hematologic malignancies.
May 22, 2026 05:00 ET | Source: BioNTech SE

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

BioNTech SE will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at ASCO 2026.